Literature DB >> 2352332

Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain.

R W Doms1, P L Earl, S Chakrabarti, B Moss.   

Abstract

The envelope (env) glycoproteins of human immunodeficiency viruses type 1 (HIV-1) and type 2 (HIV-2) form dimers shortly after synthesis. Analysis of the simian immunodeficiency virus (SIV) env protein expressed by a recombinant vaccinia virus revealed that it, too, forms stable homodimers. When the HIV-1 and SIV env proteins or the HIV-1 and HIV-2 env proteins were coexpressed in the same cells, heterodimers were formed. Thus, the env proteins of HIV-1, HIV-2, and SIV possess a functionally conserved domain involved in subunit-subunit recognition and assembly that likely involves the ectodomain of gp41.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2352332      PMCID: PMC249626     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Protein oligomerization in the endoplasmic reticulum.

Authors:  S M Hurtley; A Helenius
Journal:  Annu Rev Cell Biol       Date:  1989

2.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

3.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Genetic variation in AIDS viruses.

Authors:  J M Coffin
Journal:  Cell       Date:  1986-07-04       Impact factor: 41.582

5.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

6.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

7.  Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses.

Authors:  G Franchini; C Gurgo; H G Guo; R C Gallo; E Collalti; K A Fargnoli; L F Hall; F Wong-Staal; M S Reitz
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

Authors:  F Wong-Staal; G M Shaw; B H Hahn; S Z Salahuddin; M Popovic; P Markham; R Redfield; R C Gallo
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

9.  The chemistry of site-directed serology for HIV infections.

Authors:  E Norrby; G Biberfeld; P R Johnson; D E Parks; R A Houghten; R A Lerner
Journal:  AIDS Res Hum Retroviruses       Date:  1989-10       Impact factor: 2.205

10.  Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers.

Authors:  F Boulay; R W Doms; R G Webster; A Helenius
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

View more
  23 in total

1.  Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation.

Authors:  R J Center; P Schuck; R D Leapman; L O Arthur; P L Earl; B Moss; J Lebowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences.

Authors:  R J Center; B E Kemp; P Poumbourios
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity.

Authors:  S S Chen; S F Lee; H J Hao; C K Chuang
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Authors:  P Poumbourios; W el Ahmar; D A McPhee; B E Kemp
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Estimating the stoichiometry of HIV neutralization.

Authors:  Carsten Magnus; Roland R Regoes
Journal:  PLoS Comput Biol       Date:  2010-03-19       Impact factor: 4.475

8.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.

Authors:  Q J Sattentau; J P Moore; F Vignaux; F Traincard; P Poignard
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.

Authors:  Yuxian He; Shuwen Liu; Jingjing Li; Hong Lu; Zhi Qi; Zhonghua Liu; Asim K Debnath; Shibo Jiang
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

10.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.